Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
IQVIA Holdings Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Reportable Segments
- Analysis of Geographic Areas
- Enterprise Value (EV)
- Selected Financial Data since 2013
- Net Profit Margin since 2013
- Analysis of Revenues
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to IQVIA Holdings Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
IQVIA Holdings Inc., profitability ratios (quarterly data)
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
The financial performance across the observed periods exhibits several notable trends in profitability and efficiency metrics.
- Gross Profit Margin
- The gross profit margin showed a slight overall decline from 35.04% at the beginning of 2019 to approximately 33.44% mid-2020. This figure then stabilized and showed a gradual upward trend, reaching around 34.88% by the third quarter of 2023. This pattern suggests effective cost controls or pricing power restored after an initial dip.
- Operating Profit Margin
- The operating profit margin exhibited more variability. Starting at 7.29% in early 2019, it dipped notably to a low of about 5.55% in the third quarter of 2020, possibly reflecting operational challenges or increased expenses during that period. However, it recovered strongly afterward, peaking at over 13% by the third quarter of 2022 before slightly moderating to around 12.49% in the third quarter of 2023. This improvement indicates enhanced operational efficiency and better cost management.
- Net Profit Margin
- Net profit margin mirrored the fluctuations observed in operating margin, though at generally lower levels. It decreased from 2.35% at the start of 2019 to near 1.21% in mid-2020, then increased steadily, reaching above 8% by late 2022. This progression points to improved bottom-line profitability, potentially aided by factors such as lower interest, tax expenses, or improved operational performance. The margin remained stable around 7.5% in 2023, showing sustained profitability.
- Return on Equity (ROE)
- ROE demonstrated significant growth over the observed period, starting relatively low at 3.75% in early 2019. Despite some short-term fluctuations and a dip in 2020, ROE surged to over 22% by late 2022, before easing to roughly 19% in 2023. This development suggests improved effectiveness in utilizing shareholder equity to generate profits, reflecting solid profitability growth and possibly enhanced capital management strategies.
- Return on Assets (ROA)
- ROA followed a similar trajectory to ROE but at lower absolute values, consistent with lower asset turnover or leverage. Beginning around 1.07% in 2019, it dipped slightly below 1% during 2020 but then increased steadily, peaking near 4.88% by late 2022. The metric moderated slightly to about 4.3% in 2023. This indicates growing efficiency in asset utilization to generate net income.
Overall, the data reveals a period of subdued profitability in the early to mid-2020 timeframe, likely influenced by external challenges, followed by sustained improvements across profitability and efficiency metrics through 2022 and into 2023. Enhancements in operating performance, cost management, and capital utilization have underpinned stronger margins and returns, suggesting robust financial health moving forward.
Return on Sales
Return on Investment
Gross Profit Margin
IQVIA Holdings Inc., gross profit margin calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Gross profit margin = 100
× (Gross profitQ3 2023
+ Gross profitQ2 2023
+ Gross profitQ1 2023
+ Gross profitQ4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenue Trends
- Revenues exhibited gradual growth from March 2019 to December 2019, increasing from approximately $2.68 billion to $2.90 billion. A decline was observed in the first half of 2020, reaching around $2.52 billion in June 2020, likely influenced by macroeconomic or sector-specific challenges. Subsequently, a strong recovery took place, with revenues peaking at about $3.64 billion in December 2021. In 2022 and into 2023, revenues have stabilized at a consistently higher level than pre-2020 figures, generally fluctuating between $3.54 billion and $3.74 billion per quarter.
- Gross Profit Trends
- Gross profit followed a similar pattern to revenues. It showed moderate growth through 2019, from $936 million to $994 million. A noticeable dip occurred in mid-2020, with gross profit declining to $817 million in June 2020. Following this trough, gross profit rebounded significantly, reaching a high of $1.27 billion in December 2021. From 2022 onwards, gross profit remained robust, consistently exceeding $1.2 billion per quarter, reflecting operational recovery and increased scale.
- Gross Profit Margin Trends
- The gross profit margin percentage displayed relative stability over the reported periods. It began at around 35.0% in early 2019 but showed a modest decreasing trend during 2020, hitting a low near 33.44% in June 2020. From the latter half of 2020 onward, the margin gradually improved, rising back to close to 34.9% by late 2022 and remaining steady near that level through 2023. This suggests effective cost management or pricing improvements supporting margin restoration and enhancement after the mid-2020 decline.
- Overall Insights
- The financial data reflects resilience and recovery following a significant downturn around mid-2020, likely related to external disruptive factors. Both revenues and gross profits recovered strongly, surpassing prior peaks by late 2021. The gross profit margin, although dipping during the downturn, returned to near pre-decline levels and demonstrated marginal improvement thereafter. This indicates successful operational adjustments and potential efficiency gains, contributing to sustained profitability even as revenues grew. The stabilization of key metrics in the recent quarters suggests consolidation of this improved financial position.
Operating Profit Margin
IQVIA Holdings Inc., operating profit margin calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Income from operations | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Operating profit margin = 100
× (Income from operationsQ3 2023
+ Income from operationsQ2 2023
+ Income from operationsQ1 2023
+ Income from operationsQ4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data exhibits notable fluctuations and evolving trends in key operational metrics across the observed periods.
- Income from Operations
- The income from operations shows substantial variability across quarters. After a relatively stable start in 2019, income dipped significantly in the second quarter of 2020, reaching the lowest point during the observed timeline, likely reflecting adverse conditions in that period. Subsequently, a recovery trend ensued with a pronounced increase by the end of 2020. From 2021 through 2023, income from operations demonstrates overall growth with some quarterly fluctuations, peaking notably in the fourth quarter of 2021 and maintaining higher levels relative to the earlier years.
- Revenues
- Revenue figures indicate a general upward trajectory despite some intermittent declines. Starting from approximately 2.7 billion dollars in early 2019, revenues experienced a dip in mid-2020, mirroring the dip in operating income, followed by a strong rebound and continual growth extending into 2023. This pattern suggests resilience and progressive expansion in revenue generation capacity over time, with the highest quarterly revenues observed towards the end of the dataset in 2023.
- Operating Profit Margin
- The operating profit margin exhibits a clear positive progression throughout the entire period. Margins began slightly above 7% in 2019, declined to a low near 5.5% in mid-2020 correlating with lower operational income and revenues, but then increased steadily thereafter. By 2021 and onward, margins improved significantly, surpassing 12% and reaching a peak above 13% in late 2022. This improvement reflects enhanced operational efficiency or favorable cost management relative to revenues over time. Margins stabilized above 12% through 2023, indicating sustained profitability improvements.
Overall, the data reflects an impact likely connected to external disruptions around mid-2020, followed by recovery and growth phases. The company shows an ability to restore and increase profitability and revenues over subsequent quarters, with operating profit margins steadily improving and stabilizing at higher levels, suggesting strengthened operational performance and financial health.
Net Profit Margin
IQVIA Holdings Inc., net profit margin calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net income (loss) attributable to IQVIA Holdings Inc. | |||||||||||||||||||||||||
| Revenues | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
Net profit margin = 100
× (Net income (loss) attributable to IQVIA Holdings Inc.Q3 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q2 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q1 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q4 2022)
÷ (RevenuesQ3 2023
+ RevenuesQ2 2023
+ RevenuesQ1 2023
+ RevenuesQ4 2022)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several notable trends in key performance indicators over the observed periods.
- Net Income (Loss) Attributable to IQVIA Holdings Inc.
-
Net income demonstrates considerable variability throughout the observed quarters. Initially, net income values exhibited moderate fluctuations ranging roughly between 57 and 60 million USD, with a marked decline to 16 million USD by the end of 2019.
The first half of 2020 reflects instability, including a notable loss of 23 million USD in the second quarter. However, from mid-2020 onwards, net income trends upward significantly, recovering strongly and reaching above 100 million USD by the third quarter of 2020.
From 2021 to 2023, net income continues to grow with some periodic decreases but generally maintains a robust upward trajectory, achieving peaks above 300 million USD, indicating improved profitability and operational efficiency.
- Revenues
-
Revenues show a generally positive and steady increase over time, with some fluctuations corresponding with economic or operational conditions. Starting from about 2,684 million USD in the first quarter of 2019, revenues increased moderately until the end of 2019.
A decline is visible in the first half of 2020, likely impacted by external adverse factors, dropping to approximately 2,521 million USD in Q2 2020. However, a strong rebound commenced in the second half of 2020, with revenues reaching a peak of nearly 3,636 million USD by the fourth quarter of 2021.
Thereafter, revenue levels stabilize slightly above 3,500 million USD per quarter through 2022 and into 2023, indicating sustained business activity and market demand.
- Net Profit Margin
-
The net profit margin exhibits a discernible upward trend across the timeline. Initial margins hovered between approximately 2.24% and 2.35% in the early quarters of 2019 but declined to a low of 1.21% in the second quarter of 2020, coinciding with net income losses.
Thereafter, a consistent improvement trend emerges, with the margin expanding significantly and surpassing 6% by the end of 2021. This progression suggests enhanced cost control, pricing strategies, or operational leverage.
Between 2022 and 2023, net profit margins stabilize in a higher range between 7.2% and 8.3%, reflecting sustained profitability improvements even amidst some quarterly variances.
In summary, the financial data portrays a company that experienced some challenges in early 2020, reflected by reduced profitability and a loss quarter, likely due to macroeconomic or industry-specific disruptions. However, subsequent quarters reveal a strong recovery phase characterized by rising revenues, significantly improved net income, and expanding profit margins. The overall trajectory reflects enhanced operational performance and financial resilience in recent periods.
Return on Equity (ROE)
IQVIA Holdings Inc., ROE calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net income (loss) attributable to IQVIA Holdings Inc. | |||||||||||||||||||||||||
| Equity attributable to IQVIA Holdings Inc.’s stockholders | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
ROE = 100
× (Net income (loss) attributable to IQVIA Holdings Inc.Q3 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q2 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q1 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q4 2022)
÷ Equity attributable to IQVIA Holdings Inc.’s stockholders
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income (Loss) Attributable to IQVIA Holdings Inc.
- The net income exhibited fluctuations over the observed periods. Initially, it remained relatively stable in 2019, ranging from 16 to 60 million USD. In early 2020, a notable decline occurred with a loss of 23 million USD in June; however, subsequent quarters demonstrated recovery and growth, reaching a peak of 318 million USD by the end of 2021. Through 2022 and into 2023, net income continued at elevated levels, generally maintaining values above 225 million USD, indicating a sustained improvement in profitability compared to the earlier periods.
- Equity Attributable to IQVIA Holdings Inc.’s Stockholders
- The stockholders' equity showed a decreasing trend from the beginning of 2019 through mid-2022, falling from 6,615 million USD to a low of approximately 5,347 million USD. However, from the latter half of 2022 onward, equity values stabilized and experienced modest increases, rising to approximately 5,805 million USD by the third quarter of 2023. This pattern suggests a period of equity contraction followed by recovery or stabilization.
- Return on Equity (ROE)
- Return on equity demonstrated an overall upward trajectory throughout the periods analyzed. Starting at modest levels around 3.75% to 4.65% in 2019 and 2020, ROE saw significant improvement, surpassing 10% in mid-2021. The growth trend continued strongly through 2021 and 2022, reaching peaks above 22%. Despite a slight decline in late 2022 and early 2023, the ROE remained high, above 17%, indicating enhanced efficiency in utilizing equity to generate profits over time.
- Summary Insights
- The financial data reveals that despite some volatility in net income, particularly in early 2020, the company achieved consistent profit growth through 2021 to 2023. Although stockholders' equity contracted over several quarters, likely reflecting share buybacks, dividends, or other capital adjustments, it stabilized and slightly increased towards the latest periods. The notable rise in ROE highlights an improvement in profitability relative to equity, suggesting an effective management of resources and increased financial performance in recent years.
Return on Assets (ROA)
IQVIA Holdings Inc., ROA calculation (quarterly data)
| Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net income (loss) attributable to IQVIA Holdings Inc. | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
1 Q3 2023 Calculation
ROA = 100
× (Net income (loss) attributable to IQVIA Holdings Inc.Q3 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q2 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q1 2023
+ Net income (loss) attributable to IQVIA Holdings Inc.Q4 2022)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income (Loss) Attributable to IQVIA Holdings Inc.
- The net income exhibited notable variability over the analyzed quarters. Initial values hovered around the high 50s million US dollars in early 2019, but a significant decline occurred in the fourth quarter of 2019 with a marked drop to 16 million. The first half of 2020 showed volatility, including a negative value in Q2 2020 with a loss of 23 million, followed by recovery in the subsequent quarters. From 2021 onwards, net income demonstrated a strong upward trend, reaching a peak of 325 million in Q1 2022. Despite some fluctuation in later quarters, net income remained elevated relative to the pre-2021 period and consistently above 225 million in recent quarters up to Q3 2023.
- Total Assets
- Total assets maintained relative stability through the period, fluctuating modestly within a range of approximately 23 billion to 26 billion US dollars. There was a gradual increase from 2019 to 2020, followed by slight declines and recoveries in later years. The absolute asset value peaked in Q2 2023 at around 26.04 billion, indicating moderate asset growth development over the assessed timeframe.
- Return on Assets (ROA)
- The return on assets showed a positive trajectory throughout the period. Starting approximately at 1.07% in early 2019, ROA experienced a slight dip during 2020, likely influenced by the net income volatility, but then accelerated notably from 2021 onwards. It reached a high of 4.88% in Q3 2022 before stabilizing slightly above 4% through mid to late 2023. This pattern reflects improving profitability relative to asset base, suggesting enhanced operational efficiency or profitable utilization of assets in recent years.
- Summary of Trends
- Overall, the data reveals an improvement in financial performance characterized by rising net income and increasing return on assets over the long term despite mid-period disruptions. Total assets show steady, moderate growth without significant volatility. The enhanced ROA coupled with higher net income in recent quarters suggests effective management strategies were implemented to boost profitability and asset efficiency. The financial profile appears more robust post-2020, marking a positive momentum in the company's financial health.